Previous 10 | Next 10 |
2023-11-07 17:19:08 ET More on Genmab Genmab A/S (GMAB) Q3 2023 Earnings Call Transcript Genmab A/S 2023 Q3 - Results - Earnings Call Presentation Genmab Is Down To Attractive Levels Seagen, Genmab update Phase 3 data for uterine cancer therapy Genmab...
2023-11-07 14:32:09 ET Genmab A/S (GMAB) Q3 2023 Earnings Conference Call November 07, 2023 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & Chief Executive Officer Anthony Pagano - Executive Vice President & Chief Financial Office...
November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights Epcoritamab (TEPKINLY ® ) was granted conditional marketing authorization by the European Commission (EC) to treat adults with relapsed or re...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Genmab A/S (GMAB) is expected to report $0.34 for Q3 2023
2023-11-06 10:30:08 ET Major earnings expected before the bell on Tuesday include: Air Products and Chemicals ( APD ) Datadog ( DDOG ) D.R. Horton ( DHI ) Emerson Electric ( EMR ) Uber Technologies ( UBER ) For further details see: Notable...
Eighteen total abstracts accepted for presentation and publication, including results from four clinical trials evaluating epcoritamab in multiple treatment settings and patient populations Oral presentations highlighting new findings from a clinical trial of epcoritamab in patients with ...
2023-10-23 14:58:57 ET More on Genmab, Seagen, etc. Zai Lab Stock: De-Risking Through Market Tapping Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors Genmab Is Down To Attractive Levels Seagen/ Astellas succeed in Ph...
TIVDAK demonstrated superior overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at ESMO 2023 congress Results from innovaTV 301 intended to serve as pivotal confirmatory trial for U.S. accelerated approval an...
2023-10-18 12:46:20 ET More on Genmab Genmab Is Down To Attractive Levels Genmab A/S (GMAB) Q2 2023 Earnings Call Transcript Seagen, Genmab succeed in Phase 3 trial for cervical cancer therapy Genmab raises FY 2023 guidance on back of Darzalex sales S...
News, Short Squeeze, Breakout and More Instantly...
Genmab A/S Company Name:
GMAB Stock Symbol:
NYSE Market:
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
2024-06-27 09:00:08 ET Kaveri Pohlman from BTIG issued a price target of $47.00 for GMAB on 2024-06-27 07:34:00. The adjusted price target was set to $47.00. At the time of the announcement, GMAB was trading at $25.67. The overall price target consensus is at $41.80 with...